Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Saxagliptin (Onglyza®) is recommended as an option for use within NHS Wales as an add-on combination therapy for use in adult patients with type 2 diabetes mellitus with moderate or severe renal impairment to improve glycaemic control. AWMSG is of the opinion that saxagliptin (Onglyza®) may be suitable for shared care within NHS Wales. |
|||
|
|||
Medicine details |
|||
| Medicine name | saxagliptin (Onglyza®) | ||
| Formulation | film-coated tablet | ||
| Reference number | 1005 | ||
| Indication | Add-on combination therapy for use in adult patients with type 2 diabetes mellitus with moderate or severe renal impairment to improve glycaemic control |
||
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd/AstraZeneca UK Ltd | ||
| BNF chapter | Endocrine system | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 2011 | ||
| NMG meeting date | 03/11/2011 | ||
| AWMSG meeting date | 07/12/2011 | ||
| Ratification by Welsh Government | 09/01/2012 | ||
| Date of issue | 12/01/2012 | ||